These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16267191)

  • 21. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
    Epstein S
    Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and tolerability of i.m. disodium clodronate 200 mg/lidocaine 1%, given twice monthly, in comparison with i.m. disodium clodronate 100 mg/lidocaine 1%, given weekly, in healthy postmenopausal female patients.
    Radicioni M; Cremonesi G; Baraldi E; Leuratti C; Mariotti F
    Int J Clin Pharmacol Ther; 2013 Apr; 51(4):313-22. PubMed ID: 23357844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
    Saarto T; Vehmanen L; Blomqvist C; Elomaa I
    J Clin Oncol; 2008 Sep; 26(26):4289-95. PubMed ID: 18779616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intramuscular neridronate in postmenopausal women with low bone mineral density.
    Adami S; Gatti D; Bertoldo F; Sartori L; Di Munno O; Filipponi P; Marcocci C; Frediani B; Palummeri E; Fiore CE; Costi D; Rossini M
    Calcif Tissue Int; 2008 Nov; 83(5):301-7. PubMed ID: 18946626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intramuscular clodronate therapy in postmenopausal osteoporosis.
    Rossini M; Braga V; Gatti D; Gerardi D; Zamberlan N; Adami S
    Bone; 1999 Feb; 24(2):125-9. PubMed ID: 9951781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treating with what? Therapy for how long?].
    MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713
    [No Abstract]   [Full Text] [Related]  

  • 30. [An advantage for compliance: alendronate once weekly].
    MMW Fortschr Med; 2005 Dec; 147(49-50):75. PubMed ID: 16401017
    [No Abstract]   [Full Text] [Related]  

  • 31. [Vitamin D deficiency in postmenopausal women receiving osteoporosis therapy].
    Kraljević I; Kastelan D; Gorsić I; Solak M; Giljević Z; Kasović M; Sertić J; Korsić M
    Lijec Vjesn; 2007; 129(8-9):304. PubMed ID: 18198632
    [No Abstract]   [Full Text] [Related]  

  • 32. Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
    Brufsky AM
    Expert Opin Pharmacother; 2008 Apr; 9(6):1013-28. PubMed ID: 18377343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Teriparatide--new value in osteoporosis treatment: treatment guidelines].
    Korsić M; Kastelan D
    Reumatizam; 2006; 53(2):77-81. PubMed ID: 17580560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
    Nakamura T
    Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Calcium and vitamin D play an essential role in the prevention and treatment of osteoporosis].
    Rev Med Suisse; 2006 May; 2(66):1346. PubMed ID: 16775996
    [No Abstract]   [Full Text] [Related]  

  • 36. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO).
    Jakob F; Marín F; Martín-Mola E; Torgerson D; Fardellone P; Adami S; Thalassinos NC; Sykes D; Melo-Gomes J; Chinn C; Nicholson T; Cooper C
    QJM; 2006 Aug; 99(8):531-43. PubMed ID: 16861718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anabolic therapy for osteoporosis.
    Bilezikian JP
    Int J Fertil Womens Med; 2005; 50(2):53-60. PubMed ID: 16334411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long term effects of raloxifen on the bones].
    Eiken PA
    Ugeskr Laeger; 2008 Jan; 170(4):224-6. PubMed ID: 18282451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study.
    Benetti A; Crosignani A; Varenna M; Giussani CS; Allocca M; Zuin M; Podda M; Battezzati PM
    J Clin Gastroenterol; 2008 Mar; 42(3):306-11. PubMed ID: 18223492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A follow-up study on the effects of a milk supplement on bone mineral density of postmenopausal Chinese women in Malaysia.
    Ting GP; Tan SY; Chan SP; Karuthan C; Zaitun Y; Suriah AR; Chee WS
    J Nutr Health Aging; 2007; 11(1):69-73. PubMed ID: 17315084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.